<DOC>
	<DOCNO>NCT01657604</DOCNO>
	<brief_summary>Advances Chronic Myeloid Leukemia ( CML ) therapy lead expect survival prolongation &gt; 20 year diagnosis . So far , discontinuation tyrosine kinase inhibitor lead recurrence disease majority patient . The trial aim improve treatment strategy CML improve induction therapy deescalating maintenance therapy use low dose IFN inducer immunosurveillance . The trial provide important data duration active therapy CML patient . Considering rapidly increase prevalence CML individual also socioeconomic importance .</brief_summary>
	<brief_title>Tasigna Interferon Alpha Evaluation Initiated German Chronic Myeloid Leukemia Study Group - TIGER Study</brief_title>
	<detailed_description>Objectives Primary : - Evaluation major molecular response ( MMR ) rate 18 month nilotinib compare nilotinib+pegylated Interferon alpha ( IFN ) adult patient newly diagnose Ph/BCR-ABL CML chronic phase . - Evaluation feasibility discontinue drug therapy stable deep molecular response ( MR4 ) nilotinib versus IFN maintenance therapy . Secondary : - Evaluation efficacy tolerability IFN add nilotinib 2x300 mg/day . - Evaluation efficacy tolerability maintenance therapy nilotinib versus IFN stable MMR least 24 month nilotinib therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female patient diagnosis CPCML cytogenetic confirmation Ph chromosome [ ( 9 ; 22 ) ( q34 ; q11 ) ] Ph negative case patient variant translocation BCRABL positive multiplex PCR ( Cross , et al 1994 ) eligible well ECOG performance status &lt; 2 Pretreatment hydroxyurea 6 month imatinib nilotinib duration 6 week permit Age ≥ 18 year old ( upper age limit give ) Normal serum level ≥ LLN ( low limit normal ) potassium , magnesium , total calcium correct serum albumin , correct within normal limit supplement ASAT ALAT ≤ 2.5 x ULN ( upper limit normal ) ≤ 5.0 x ULN consider due leukemia Alkaline phosphatase ≤ 2.5 x ULN unless consider due leukemia Total bilirubin ≤ 1.5 x ULN , except know Mb . Gilbert Serum lipase amylase ≤ 1.5 x ULN Serum creatinine ≤ 2 x ULN Written inform consent prior study procedure perform Known impaired cardiac function , include follow : Left ventricular ejection fraction ( LVEF ) &lt; 45 % Congenital long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec screen ECG . If QTc &gt; 450 m electrolyte within normal range nilotinib dose , electrolyte correct patient rescreened QTc criterion Myocardial infarction within 12 month prior start therapy Other clinical significant heart disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ) History acute ( i.e. , within 1 year start study medication ) chronic pancreatitis Acute chronic viral hepatitis moderate severe hepatic impairment ( ChildPugh score &gt; 6 ) , even control Other concurrent uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection , acute chronic liver renal disease ) could cause unacceptable safety risk compromise compliance protocol Impaired gastrointestinal function disease may alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Concomitant medication potential QT prolongation Concomitant medication know strong inducer inhibitor CYP450 isoenzyme CYP3A4 Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy Patients pregnant breast feeding , woman reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 14 day prior administration nilotinib ) . Post menopausal woman must amenorrheic least 12 month order consider nonchildbearing potential . Female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) Active autoimmune disorder , include autoimmune hepatitis Known serious hypersensitivity reaction peginterferon alfa2b interferon alfa2b drug excipients Known serious hypersensitivity reaction nilotinib Patients history another primary malignancy currently clinically significant currently require active intervention Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>CML</keyword>
	<keyword>Tasigna</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Interferon</keyword>
</DOC>